Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company dedicated to developing novel cancer therapies. Leveraging their proprietary PLK1 inhibition technology, Cardiff Oncology focuses on creating innovative treatments for various cancers with significant unmet medical needs.
Cardiff Oncology's lead therapeutic asset is onvansertib, a highly selective Polo-like kinase 1 (PLK1) inhibitor. This investigational drug is currently being evaluated in clinical trials for its effectiveness in treating multiple types of cancer, including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Recent achievements include promising clinical data for onvansertib monotherapy and combination therapy in mPDAC and SCLC trials. The mPDAC Phase 2 trial reported a 19% objective response rate (ORR) and a median progression-free survival (mPFS) of 5.0 months, compared to historical controls with an ORR of 7.7% and mPFS of 3.1 months. In SCLC, onvansertib monotherapy has demonstrated encouraging single-agent activity.
Cardiff Oncology continues to expand its clinical programs and research partnerships. They announced a first-line trial in mPDAC in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute, exploring both monotherapy and combination therapy with standard care. Furthermore, the company highlights an ongoing Phase 1b/2 study for KRAS-mutated mCRC, which has shown a favorable safety profile and promising efficacy results.
Financially, Cardiff Oncology reported a strong cash position with approximately $81.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Their operational strategy is supported by partnerships and ongoing research endeavors, which are projected to fund operations into 2025.
The company's forward-looking initiatives include the advancement of their lead program in RAS-mutated mCRC to the first-line setting and continuous exploration of onvansertib's potential in various cancer treatments. Investors and stakeholders can stay updated through regular business updates and conference calls hosted by Cardiff Oncology.
Cardiff Oncology (Nasdaq: CRDF) announced the dosing of the first patient in its Phase 2 ONSEMBLE trial of onvansertib, aimed at treating KRAS/NRAS-mutated metastatic colorectal cancer (mCRC). This trial seeks to demonstrate a significant improvement in treatment response when combining onvansertib with the standard of care, FOLFIRI/bevacizumab. The primary endpoint focuses on objective response rates, while secondary endpoints include progression-free survival and overall survival. The trial is being conducted at nearly half of the planned 40 sites in the U.S., showing strong interest from investigators.
Cardiff Oncology (Nasdaq: CRDF) announced the formal introduction of its Scientific Advisory Board (SAB) on March 6, 2023. The SAB consists of esteemed leaders in oncology drug development and will guide the advancement of onvansertib, the company's lead asset targeting various cancers, including metastatic colorectal and pancreatic cancers. Notable members include Dr. Scott Kopetz and Dr. Heinz-Josef Lenz, among others, who bring extensive expertise in clinical research. The SAB is expected to expand its membership to enhance expertise in new clinical indications, reinforcing Cardiff's commitment to improving cancer treatment options.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced promising Phase 1b/2 trial results for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), showing an objective response rate of 35%, significantly higher than historical controls. The company has a strong cash position of approximately $105.3 million as of December 31, 2022, projected to fund operations into 2025. Recent leadership appointments include Dr. Fairooz Kabbinavar as CMO, enhancing clinical expertise. Upcoming data readouts from clinical trials in mPDAC, SCLC, TNBC, and the ONSEMBLE trial are expected in 2023 and beyond, potentially advancing onvansertib's market position in oncology.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm focused on PLK1 inhibition for cancer therapies, announced its participation in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, at Boston Marriott Copley Place. Management will join a corporate panel discussion and conduct one-on-one investor meetings. The GI/GU Oncology panel discussion is scheduled for March 7 at 12:50 PM ET, with a webcast available for attendees. A replay will be accessible on the Cardiff Oncology website for 30 days post-conference.
For more details, visit Cardiff Oncology.
Cardiff Oncology (Nasdaq: CRDF) has appointed Dr. Fairooz Kabbinavar as its new chief medical officer, effective January 30, 2023. With over 30 years of experience in oncology, Dr. Kabbinavar will lead the clinical development of onvansertib, a promising treatment for colorectal cancer and other solid tumors. His prior roles include significant contributions to the approval of bevacizumab for metastatic colorectal cancer. His expertise aims to streamline Cardiff's clinical programs, particularly those targeting KRAS-mutated metastatic colorectal cancer. The Board has granted him 425,000 stock options at an exercise price of $1.75 per share.
Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The chat will take place on January 18 at 1:30 PM ET. Investors can register for the live webcast through the provided link. Cardiff Oncology is focused on developing therapies leveraging PLK1 inhibition to treat various cancers, including KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. For more details, visit their official website.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 3:55 PM GMT (10:55 AM ET) and will include a corporate presentation followed by a Q&A session. The company focuses on PLK1 inhibition in developing therapies for cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. A replay will be available on their website for 90 days.
Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 trial results for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), showing durable responses and positioning for a Phase 2 trial, ONSEMBLE, set to start in Q4 2022. As of September 30, 2022, the company has approximately $114 million in cash, projected to fund operations into 2025. The objective response rate for patients was 35%, significantly exceeding historical controls, with better outcomes in bevacizumab-naïve patients (ORR 69%).
Cardiff Oncology (CRDF) announced plans for a randomized Phase 2 trial, ONSEMBLE, to evaluate onvansertib's efficacy in second-line RAS-mutated metastatic colorectal cancer (mCRC), with topline data expected in 2H 2024. The ongoing Phase 1b/2 trial shows a median duration of response of 11.7 months. Initial results in a Phase 2 trial for pancreatic cancer indicate promising responses. The company's cash resources are projected to cover operations into 2025, emphasizing a strategic focus on mCRC and pancreatic cancer while discontinuing prostate cancer activities.
Cardiff Oncology (Nasdaq: CRDF) announced promising results from its Phase 1b/2 clinical trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a median duration of response (mDoR) of 11.7 months and an overall response rate (ORR) of 35%, surpassing historical benchmarks. Additionally, patients with a ≥90% decrease in KRAS mutant allele frequency showed significantly better outcomes. These findings suggest onvansertib may address critical treatment gaps in mCRC, with further data presented at ESMO Congress 2022.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
What is Cardiff Oncology's primary focus?
What is onvansertib?
Which cancers is Cardiff Oncology targeting with onvansertib?
What are the recent clinical achievements of Cardiff Oncology?
What is the financial condition of Cardiff Oncology?
What are the upcoming milestones for Cardiff Oncology?
How can investors stay updated about Cardiff Oncology?
What partnerships does Cardiff Oncology have?
What is the significance of PLK1 in cancer treatment?
Where can more information about Cardiff Oncology be found?
